SCHEMBL20338992

SCHEMBL20338992

COc1ccc(CN(C)Cc2cc(Nc3ccc(C)cc3)nc(N)n2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 3/20 0.56
MAPT P10636 8/20 0.52
POLB P06746 2/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
GAA P10253 1/20 0.52
DHFR P00374 4/20 0.46
MEN1 O00255 2/20 0.46
LMNA P02545 2/20 0.46
KMT2A Q03164 2/20 0.46
L3MBTL1 Q9Y468 2/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C19 P33261 1/20 0.41
TP53 P04637 1/20 0.41
SLC2A1 P11166 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
ALDH1A1 P00352 2/20 0.40
KDM4E B2RXH2 2/20 0.40
NPC1 O15118 1/20 0.40
JAK2 O60674 1/20 0.40
PKM P14618 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20340282 0.92 RAB9A (0.44) RAB9AMAPTPOLBSMN1; SMN2GAA
SCHEMBL21530423 0.90 RAB9A (0.54) RAB9AMAPTPOLBSMN1; SMN2GAA
SCHEMBL29621881 0.89 RAB9A (0.47) RAB9AMAPTPOLBSMN1; SMN2GAA
SCHEMBL29621839 0.89 RAB9A (0.47) RAB9AMAPTPOLBSMN1; SMN2GAA
SCHEMBL20355770 0.89 RAB9A (0.47) RAB9AMAPTPOLBSMN1; SMN2GAA
SCHEMBL20339003 0.89 RAB9A (0.47) RAB9AMAPTPOLBSMN1; SMN2GAA
SCHEMBL20338986 0.87 NPC1 (0.54) RAB9AMAPTPOLBSMN1; SMN2GAA
SCHEMBL20339039 0.86 CYP1A2 (0.49) RAB9AMAPTPOLBSMN1; SMN2DHFR
SCHEMBL20340278 0.86 ROCK1 (0.52) RAB9AMAPTPOLBSMN1; SMN2GAA
SCHEMBL29621866 0.86 ROCK1 (0.52) RAB9AMAPTPOLBSMN1; SMN2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11739072-B2 Heteroaryl compounds and their use MINORYX THERAPEUTICS S.L. (ES) 2023-08-29 US disclosed
US-11739072-B2 Heteroaryl compounds and their use MINORYX THERAPEUTICS S.L. (ES) 2023-08-29 US disclosed
US-11739072-B2 Heteroaryl compounds and their use MINORYX THERAPEUTICS S.L. (ES) 2023-08-29 US disclosed
US-20220135535-A1 HETEROARYL COMPOUNDS AND THEIR USE MINORYX THERAPEUTICS S.L. (ES) 2022-05-05 US disclosed
US-20220135535-A1 HETEROARYL COMPOUNDS AND THEIR USE MINORYX THERAPEUTICS S.L. (ES) 2022-05-05 US disclosed
EP-3562811-B1 HETEROARYL COMPOUNDS AND THEIR USE MINORYX THERAPEUTICS S L (ES) 2022-03-16 EP disclosed
US-11174242-B2 Heteroaryl compounds and their use MINORYX THERAPEUTICS S.L. (ES) 2021-11-16 US disclosed
US-11174242-B2 Heteroaryl compounds and their use MINORYX THERAPEUTICS S.L. (ES) 2021-11-16 US disclosed
US-20190337922-A1 HETEROARYL COMPOUNDS AND THEIR USE MINORYX THERAPEUTICS S.L. (ES) 2019-11-07 US disclosed
EP-3562811-A1 HETEROARYL COMPOUNDS AND THEIR USE Minoryx Therapeutics S.L. (ES) 2019-11-06 EP disclosed
WO-2018122775-A1 HETEROARYL COMPOUNDS AND THEIR USE MINORYX THERAPEUTICS S.L. (ES) 2018-07-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220135535-A1 HETEROARYL COMPOUNDS AND THEIR USE GBA1, GBA2, GAA RAB9A 83/4885MAPT 229/4885POLB 1588/4885
US-20190337922-A1 HETEROARYL COMPOUNDS AND THEIR USE GBA1, GBA2, GAA RAB9A 83/4885MAPT 229/4885POLB 1588/4885
US-11174242-B2 Heteroaryl compounds and their use GBA1, GBA2, GAA RAB9A 83/4885MAPT 229/4885POLB 1588/4885
US-11739072-B2 Heteroaryl compounds and their use GBA1, GBA2, GAA RAB9A 83/4885MAPT 229/4885POLB 1588/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.